NIVESTYM offers the potential to help address treatment costs, while maintaining the established clinical efficacy and safety profile of filgrastim—brought to you by Pfizer, a committed leader in biosimilar innovation and development2
*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar and the reference product.2
WAC is a manufacturer’s undiscounted or list price to wholesalers/direct purchasers and, therefore, is not inclusive of discounts to payers, providers, distributors, and other purchasing organizations.
Represents WAC for 480-mcg prefilled syringe (PFS) only. Granix costs represent 480-mcg PFS with the safety needle guard. Costs as of July 2018.
§There are no head-to-head studies between Granix, Zarxio, and NIVESTYM, and no clinical comparisons can be made between the products.
Granix is approved for one indication. Please refer to the full Prescribing Information for each product for full indication(s).